Analysts Offer Insights on Healthcare Companies: Fibrocell Science Inc (FCSC) and Amag Pharmaceuticals (AMAG)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fibrocell Science Inc (FCSC) and Amag Pharmaceuticals (AMAG).

Fibrocell Science Inc (FCSC)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Fibrocell Science Inc, with a price target of $22. The company’s shares opened today at $2.01, close to its 52-week low of $1.75.

Pantginis noted:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV).”

According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -17.3% and a 26.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.

Fibrocell Science Inc has an analyst consensus of Moderate Buy, with a price target consensus of $22.

See today’s analyst top recommended stocks >>

Amag Pharmaceuticals (AMAG)

Cantor Fitzgerald analyst William Tanner reiterated a Hold rating on Amag Pharmaceuticals today and set a price target of $18. The company’s shares opened today at $17.50.

Tanner wrote:

“We reiterate the Neutral rating and $18 PT for AMAG stock. We believe the next 12-18 months will be a critical period for the company in demonstrating that other assets, namely, Vyleesi can blunt the impact of generic competition for Makena and contribute to an attractive out year top- and bottom-line growth trajectory.”

According to TipRanks.com, Tanner is a 1-star analyst with an average return of -0.7% and a 38.9% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Intra-Cellular Therapies, and Evofem Biosciences Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Amag Pharmaceuticals with a $21.14 average price target, which is a 20.8% upside from current levels. In a report issued on November 1, Cowen & Co. also maintained a Hold rating on the stock with a $19 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts